Cosmos Health Cuts Total Debt by Over a Third While Posting Record Sales

Cosmos Health Cuts Total Debt by Over a Third While Posting Record Sales

2026-11-18 companies

Chicago, Wednesday, 18 November 2026.
Cosmos Health achieved record nine-month sales of $53.59 million and eliminated an $8 million convertible note early, reducing total debt by 34% and strengthening its balance sheet.

Record Revenue Growth Amid Strategic Debt Reduction

Cosmos Health Inc. (NASDAQ: COSM) has delivered a standout financial performance for the first nine months of 2026, reporting record revenue of $53.59 million—a 17.6% increase from $45.57 million in the same period last year [1]. This growth was underpinned by strong momentum across its core operating segments, including pharmaceutical distribution, contract manufacturing, and proprietary branded products. The company’s third-quarter results further underscored its operational strength, with gross margin expanding sequentially by 465 basis points to 12.6% [1]. Adjusted EBITDA also improved by approximately 18% from the prior quarter, signaling enhanced profitability despite ongoing market challenges [1]. CEO Greg Siokas emphasized the company’s progress, stating, ‘We delivered record nine-month revenue of $53.6 million, up 18%, driven by strong momentum across our core segments’ [1][7].

Balance Sheet Transformation Through Early Debt Retirement

A key highlight of Cosmos Health’s third-quarter performance was its aggressive debt reduction strategy. The company fully settled an $8.0 million convertible note ahead of its August 2027 maturity, cutting total debt by 34% since the beginning of the year [1][8]. This move not only reduced the company’s debt burden but also significantly improved its financial flexibility, as reflected in a debt-to-equity ratio that declined from 1.05x to 0.57x [1]. Stockholders’ equity rose by 21.2% to $22.33 million, marking the third consecutive quarterly increase and underscoring the company’s strengthened capital structure [1][8]. Additionally, working capital surged to $2.34 million from just $0.12 million at the end of 2025, providing further evidence of improving liquidity [1]. These financial improvements were complemented by the company’s ongoing share repurchase program, which has seen 255,600 shares (5,112,000 pre-split) repurchased for approximately $1.15 million to date [1][7].

Operational Momentum and Future Growth Initiatives

Cosmos Health is entering the final quarter of 2026 with robust operational momentum. The company’s contract manufacturing pipeline has reached a record 32.7 million units, while its U.S. direct-to-consumer business has surpassed 12,500 active subscriptions, generating $1.83 million in monthly subscription value ($22 million annualized) [1]. On the distribution front, CosmoFarm’s pharmacy network has expanded to include approximately 1,500 locations, with daily service to around 360 pharmacies [1]. Looking ahead, Cosmos Health has outlined ambitious plans to tokenize its CCX0722 hydrogel intellectual property, targeting the $562 billion global weight-management market. This initiative, which aims to leverage blockchain technology for non-dilutive financing, reflects the company’s innovative approach to capital deployment [1][7]. Furthermore, the company has reaffirmed its full-year 2026 guidance of $90 million+ in revenue and its 2029 target of $200.6 million, underpinned by a projected 32% compound annual growth rate [1][9].

Market Response and Regulatory Context

Cosmos Health’s financial turnaround has been met with cautious optimism by investors. The company’s stock, which underwent a 1-for-20 reverse split on November 13, 2026, has seen mixed performance in recent weeks, with a 10.8% decline over the past 30 days offset by a 38% gain over the trailing quarter [4][10]. Analysts have noted the company’s progress but remain cautious due to its micro-cap status and elevated volatility [4]. On the regulatory front, Cosmos Health recently filed a Notification of Late Filing with the SEC regarding its Form 10-Q for the period ended September 30, 2026, citing difficulties in compiling XBRL data [5]. Despite this, the company has confirmed that no significant changes to its operational results are anticipated, and it remains on track to file the report within the prescribed timelines [5]. The company’s ability to navigate these challenges while delivering strong financial results underscores its resilience in a complex economic environment.

Sources


Earnings report Cosmos Health